Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go:
Expired
investment:
£5,083,686
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
Bank of Telecom is the global marketplace for secure voices trade. Members have access to live traffic and pricing and can post routes on their own terms and pricing to ensure simple and secure trading.
days to go:
Expired
investment:
£450,000
GalleriesNow is a revolutionary art platform rapidly becoming the most trusted source of information on galleries, artists and exhibitions worldwide. We have achieved tremendous traction in the space of one year, already working with Frieze Art Fair, Soho House and the FT and in discussions with major arts publications - and are an increasingly valuable way for galleries to interact with their audiences. We are fundraising to consolidate and bring further revenue streams on-line. Our goal is to be the perfect bridge between gallery and art buyer - join us on our journey!
days to go:
Expired
investment:
£33,384
Total Be wants to bring an internationally recognised model of car insurance to the UK. It provides insurance for the car, not just for an individual driver. Additionally, it does not take crime data into account that is not specific to vehicles. Thus, this insurance is estimated to provide up to 25% cheaper cover in comparison to UK insurance. Moreover, a UK Government Petition for this insurance model has gained over 60,000+ signatures, which further validates the demand of this model. Total Be believes that it will be able to disrupt the UK market with this car insurance model.
days to go:
Expired
investment:
£150,760
